Dronedarone hydrochloride inhibits gastric cancer proliferation in vitro and in vivo by targeting SRC
Our research has revealed that Dronedarone hydrochloride, an FDA-approved drug, is an SRC inhibitor that can suppress the growth of GC cells by blocking the SRC/AKT1 signaling pathway. It provides a scientific basis for use in the clinical treatment of GC.
Authors
- Xuebo Lu
- Baoyin Yuan (ORCID: https://orcid.org/0000-0003-4782-1271)
- Zigang Dong (ORCID: https://orcid.org/0000-0002-4174-4028)
- Xiaoxiao Yang (ORCID: https://orcid.org/0000-0002-9219-1371)
- Weizhe Zhang (ORCID: https://orcid.org/0000-0003-4783-876X)
- Jinmin Zhao
- Kangdong Liu
- Qiong Wu (ORCID: https://orcid.org/0000-0003-1943-985X)
- Yanan Jiang (ORCID: https://orcid.org/0000-0001-6129-643X)
- Ke Yao (ORCID: https://orcid.org/0000-0002-0245-6445)
- Zubair Butt Hussain (ORCID: https://orcid.org/0000-0002-3562-8848)
- Xiao Yan (ORCID: https://orcid.org/0009-0004-6220-9608)
Institutions
- Zhengzhou University (CN)
- Henan Tianguan Group (China) (CN)
- China-US (Henan) Hormel Cancer Institute (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-10-05
- DOI
- https://doi.org/10.1016/j.tranon.2024.102136
- Citations
- 4
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- National Natural Science Foundation of China
- Science and Technology Innovation Talents in Universities of Henan Province